{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T16:25:36Z","timestamp":1777825536494,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Program for Basic and Clinical Research on Hepatitis, Japan Agency for Medical Research and Development","award":["JP23fk0210084"],"award-info":[{"award-number":["JP23fk0210084"]}]},{"DOI":"10.13039\/100012832","name":"Okinaka Memorial Institute for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00535-023-02046-y","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T06:01:37Z","timestamp":1697263297000},"page":"34-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5232-796X","authenticated-orcid":false,"given":"Fumitaka","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Sezaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichiro","family":"Fujiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuji","family":"Arase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"key":"2046_CR1","unstructured":"Global Hepatitis Report, 2017. World Health Organization (WHO). 2017 http:\/\/apps.who.int\/iris\/bitstream\/10665\/255016\/1\/9789241565455-eng.pdf?ua=1"},{"key":"2046_CR2","doi-asserted-by":"crossref","unstructured":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the management of hepatitis B virus infection: 2019 update. Hepatol Res. 2020;50:892\u2013923.","DOI":"10.1111\/hepr.13504"},{"key":"2046_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, et al. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u201383.","journal-title":"Hepatology"},{"key":"2046_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver EASL","year":"2017","unstructured":"European Association for the Study of the Liver EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"2046_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398.","journal-title":"Hepatol Int"},{"key":"2046_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2046_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2046_CR8","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325\u201332.","journal-title":"Gut"},{"key":"2046_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/hepr.13602","volume":"51","author":"F Suzuki","year":"2021","unstructured":"Suzuki F, Hosaka T, Imaizumi M, et al. Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Hepatol Res. 2021;51:426\u201335.","journal-title":"Hepatol Res"},{"key":"2046_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","volume":"70","author":"TC Yip","year":"2019","unstructured":"Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70:361\u201370.","journal-title":"J Hepatol"},{"key":"2046_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00535-018-1502-y","volume":"54","author":"F Suzuki","year":"2019","unstructured":"Suzuki F, Hosaka T, Suzuki Y, et al. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-na\u00efve chronic hepatitis B patients in Japan. J Gastroenterol. 2019;54:182\u201393.","journal-title":"J Gastroenterol"},{"key":"2046_CR12","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/hep.20240","volume":"39","author":"MF Yuen","year":"2004","unstructured":"Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology. 2004;39:1694\u2013701.","journal-title":"Hepatology"},{"key":"2046_CR13","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","volume":"135","author":"MF Yuen","year":"2008","unstructured":"Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135:1192\u20139.","journal-title":"Gastroenterology"},{"key":"2046_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/hep.26376","volume":"58","author":"WK Seto","year":"2013","unstructured":"Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013;58:923\u201331.","journal-title":"Hepatology"},{"key":"2046_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00535-015-1128-2","volume":"51","author":"WK Seto","year":"2016","unstructured":"Seto WK, Cheung KS, Wong DK, et al. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. J Gastroenterol. 2016;51:487\u201395.","journal-title":"J Gastroenterol"},{"key":"2046_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jhep.2021.02.017","volume":"75","author":"T Inoue","year":"2021","unstructured":"Inoue T, Kusumoto S, Iio E, et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol. 2021;75:302\u201310.","journal-title":"J Hepatol"},{"key":"2046_CR17","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1136\/gutjnl-2019-320015","volume":"69","author":"MA Kim","year":"2020","unstructured":"Kim MA, Kim SU, Sinn DH, et al. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut. 2020;69:2214\u201322.","journal-title":"Gut"},{"key":"2046_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000098958","volume":"50","author":"Y Arase","year":"2007","unstructured":"Arase Y, Suzuki F, Suzuki Y, et al. Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirology. 2007;50:161\u20135.","journal-title":"Intervirology"},{"key":"2046_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/cid\/cir755","volume":"54","author":"CM Chu","year":"2012","unstructured":"Chu CM, Liaw YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis. 2012;54:88\u201390.","journal-title":"Clin Infect Dis"},{"key":"2046_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","volume":"40","author":"T Kimura","year":"2002","unstructured":"Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439\u201345.","journal-title":"J Clin Microbiol"},{"key":"2046_CR21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1046\/j.1365-2893.2003.00437.x","volume":"10","author":"A Rokuhara","year":"2003","unstructured":"Rokuhara A, Tanaka E, Matsumoto A, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat. 2003;10:324\u201330.","journal-title":"J Viral Hepat"},{"key":"2046_CR22","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1128\/JCM.00366-07","volume":"45","author":"DK Wong","year":"2007","unstructured":"Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:3942\u20137.","journal-title":"J Clin Microbiol"},{"key":"2046_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/jmv.21339","volume":"81","author":"F Suzuki","year":"2009","unstructured":"Suzuki F, Miyakoshi H, Kobayashi M, et al. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol. 2009;81:27\u201333.","journal-title":"J Med Virol"},{"key":"2046_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","volume":"40","author":"T Kimura","year":"2002","unstructured":"Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus corerelated antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439\u201345.","journal-title":"J Clin Microbiol"},{"key":"2046_CR25","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jhep.2011.06.006","volume":"55","author":"HL Chan","year":"2011","unstructured":"Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011\u2014a core group report. J Hepatol. 2011;55:1121\u201331.","journal-title":"J Hepatol"},{"key":"2046_CR26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","volume":"70","author":"B Testoni","year":"2019","unstructured":"Testoni B, Lebosse F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70:615\u201325.","journal-title":"J Hepatol"},{"key":"2046_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/apt.15108","volume":"49","author":"T Hosaka","year":"2019","unstructured":"Hosaka T, Suzuki F, Kobayashi M, et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment Pharmacol Ther. 2019;49:457\u201371 (Erratum in: Aliment Pharmacol Ther 2019;50:234\u20135).","journal-title":"Aliment Pharmacol Ther"},{"key":"2046_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hep4.1819","volume":"6","author":"T Hosaka","year":"2022","unstructured":"Hosaka T, Suzuki F, Kobayashi M, et al. Ultrasensitive assay for hepatitis B core-related antigen predicts hepatocellular carcinoma incidences during entecavir. Hepatol Commun. 2022;6:36\u201349.","journal-title":"Hepatol Commun"},{"key":"2046_CR29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00535-022-01918-z","volume":"57","author":"YF Liaw","year":"2022","unstructured":"Liaw YF. Perspectives on current controversial issues in the management of chronic HBV infection. J Gastroenterol. 2022;57:828\u201337.","journal-title":"J Gastroenterol"},{"key":"2046_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","volume":"70","author":"WK Seto","year":"2021","unstructured":"Seto WK, Liu KS, Mak LY, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut. 2021;70:775\u201383.","journal-title":"Gut"},{"key":"2046_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00535-023-01970-3","volume":"58","author":"X Chang","year":"2023","unstructured":"Chang X, Li Y, Sun C, et al. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy. J Gastroenterol. 2023;58:481\u201393.","journal-title":"J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-02046-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-02046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T16:08:12Z","timestamp":1704298092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-02046-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2046"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-02046-y","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,14]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Suzuki F has received lecture fees from Gilead Sciences Inc. Hosaka has received lecture fees from Gilead Sciences Inc. Akuta has received lecture fees from Abbvie GK. Kawamura has received lecture fees from Eisai Co., Ltd. Kumada has received investigator, lecture and consulting fees from Gilead Sciences Inc., Abbvie GK, Eisai Co., Ltd, Chugai Pharmaceutical Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}